Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Research & Development (2020 - 2026)

Rani Therapeutics Holdings' Research & Development history spans 7 years, with the latest figure at $5.2 million for Q1 2026.

  • On a quarterly basis, Research & Development fell 21.45% to $5.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $18.8 million, a 26.77% decrease, with the full-year FY2025 number at $20.2 million, down 24.27% from a year prior.
  • Research & Development came in at $5.2 million for Q1 2026, up from $4.9 million in the prior quarter.
  • The five-year high for Research & Development was $11.2 million in Q3 2023, with the low at $3.2 million in Q3 2025.
  • Historically, Research & Development has averaged $7.5 million across 5 years, with a median of $7.6 million in 2024.
  • Biggest five-year swings in Research & Development: skyrocketed 153.47% in 2022 and later crashed 47.81% in 2025.
  • Year by year, Research & Development stood at $10.4 million in 2022, then fell by 26.77% to $7.6 million in 2023, then decreased by 10.47% to $6.8 million in 2024, then decreased by 27.91% to $4.9 million in 2025, then grew by 5.13% to $5.2 million in 2026.
  • Business Quant data shows Research & Development for RANI at $5.2 million in Q1 2026, $4.9 million in Q4 2025, and $3.2 million in Q3 2025.